OXYCONTIN Drug Patent Profile

Which patents cover Oxycontin, and what generic alternatives are available?

Oxycontin is a drug marketed by Knoa Pharma and is included in one NDA. There are fifteen patents protecting this drug and five Paragraph IV challenges.

This drug has two hundred and twenty-one patent family members in forty countries.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oxycontin

A generic version of OXYCONTIN was approved as oxycodone hydrochloride by SPECGX LLC on June 30^th, 2004.

Summary for OXYCONTIN

International Patents:	221
US Patents:	15
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OXYCONTIN

Paragraph IV (Patent) Challenges for OXYCONTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	20 mg	022272	2	2010-10-29
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	15 mg	022272	1	2010-10-28
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	10 mg	022272	1	2010-10-25
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	30 mg, 60 mg and 80 mg	022272	1	2010-10-18
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	40 mg	022272	1	2010-10-04

US Patents and Regulatory Information for OXYCONTIN

OXYCONTIN is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Knoa Pharma	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-005	Apr 5, 2010		RX	Yes	Yes	8,894,988		Y
Knoa Pharma	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-007	Apr 5, 2010		RX	Yes	No	11,964,056		Y
Knoa Pharma	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-003	Apr 5, 2010		RX	Yes	No	9,763,933		Y

International Patents for OXYCONTIN

See the table below for patents covering OXYCONTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	045352	FORMA DE DOSIFICACION A PRUEBA DE ABUSO
Argentina	045353	FORMA DE DOSIFICACION A PRUEBA DE ABUSO
Argentina	046994	PROCESO PARA LA PRODUCCION DE UNA FORMA DE DOSIFICACION A PRUEBA DE ABUSO

Supplementary Protection Certificates for OXYCONTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

OXYCONTIN (Oxycodone Hydrochloride Extended-Release): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

OXYCONTIN, the brand name for extended-release oxycodone, is a prominent opioid analgesic primarily used for managing chronic pain. Since its approval in 1995 by the FDA, OxyContin has experienced a complex market trajectory, influenced by regulatory changes, opioid epidemic concerns, and shifting prescribing behaviors. This report analyzes the current investment landscape, market dynamics, and financial prospects for OXYCONTIN, providing insights into future opportunities and risks.

---

1. Market Overview

Aspect	Details
Therapeutic Area	Chronic pain management
Global Market Size (2022)	Estimated at USD 8.9 billion (MarketWatch)
Compound Annual Growth Rate (CAGR) (2022–2027)	~4%
Major Competitors	Purdue Pharma's OxyContin (marketed in the US), other extended-release opioids (e.g., hydromorphone ER), non-opioid alternatives

Source: [1], [2]

---

2. Regulatory and Legal Environment

2.1 Regulatory Challenges

• The US FDA and DEA have implemented stricter prescribing regulations post-2010 amid opioid misuse crisis.

Policy/Regulation	Description	Impact
PDMPs (Prescription Drug Monitoring Programs)	State-level tracking systems	Reduced high-dose opioid prescribing
Rescheduling (2017)	Rescheduled oxycodone from schedule II to III in some jurisdictions	Limited access, impacted sales
Ongoing Litigation	Dozens of lawsuits against Purdue, others for opioid crisis roles	Potential penalties, influence on prescribing trends

Impact: Regulatory reforms have decreased OXYCONTIN prescriptions but also spurred innovation in pain management modalities.

2.2 Patent and Market Exclusivity

• Original patent expired in the US (2013), allowing generics entry.
• Purdue’s formulation patents (pain management devices, abuse-deterrent versions) have faced challenges, leading to increased generic competition.

Note: As of 2023, multiple generics are available, reducing brand-specific market share.

---

3. Market Dynamics

3.1 Prescription Trends and Usage

Year	US Prescriptions (millions)	Market Share of OXYCONTIN	Notes
2010	157	~65%	Dominant brand in ER opioids
2015	120	~40%	Growing generic competition
2020	70	~20%	Regulatory impact, shift towards non-opioid therapies

Source: [3], [4]

3.2 Impact of the Opioid Epidemic

• Decreased prescriptions: From 2010 peak, substantial decline (~55%) by 2020.
• Legal actions: Purdue Pharma filed for bankruptcy (2021) amidst liabilities.

3.3 Innovation and Reformulation

• Abuse-deterrent formulations (ADFs) developed to reduce misuse.
• FDA approval of reformulated OXYCONTIN with abuse-deterrent properties in 2010.

3.4 Market Segmentation and Geographic Variability

Segment	Characteristics	Key Insights
Hospitals	Acute pain, post-surgical	Controlled prescribing
Palliative	End-of-life care	Steady demand
Chronic pain clinics	Long-term management	Decreasing due to regulation

Geographies	Trends	Notes
US	Decline in prescriptions	Increased scrutiny
Europe	Steady but cautious growth	Regulatory divergence

---

4. Financial Trajectory and Investment Outlook

4.1 Revenue Generation

Year	Revenue (USD billion)	Change	Key Drivers
2015	~USD 1.2	-	Generic penetration increasing
2020	~USD 0.6	-50%	Regulatory crackdown, societal pressure
2022	~USD 0.4	Further decline	Continued regulation, shift to alternatives

4.2 Profitability and Cost Structure

• Gross Margin: Estimated at 60–65% pre-generic entry.
• Cost of Goods Sold (COGS): Moderate, with manufacturing complexities.
• Legal Liabilities: Significant contingency liabilities from lawsuits.

4.3 Strategic Opportunities

Opportunity	Rationale	Challenges
Abuse-deterrent formulations	Mitigate misuse, regain market share	Development costs, limited reimbursement
Combination products	Mix with non-opioid analgesics	Regulatory hurdles
Market expansion in emerging markets	Growing pain management needs	Regulatory and pricing barriers

4.4 Risks

Risk	Description	Impact
Regulatory tightening	Further restrictions on opioid prescribing	Revenue decline
Legal liabilities	Multi-billion-dollar lawsuits	Financial strain
Public perception	Negative stigma	Prescribing reduction

---

5. Comparative Analysis: OXYCONTIN Versus Competitors

Attribute	OXYCONTIN	Immediate-Release Oxycodone	Other ER Opioids	Non-Opioid Pain Therapies
Formulation	Extended-release	Immediate-release	Varies	Varies
Reformulation with Abuse Deterrence	Yes (2010)	No	Yes	No
Market Leadership (historical)	Yes (pre-2013)	N/A	N/A	N/A
Regulatory Status	Restricted post-2010	Less restrictive	Varies	Less regulated

---

6. Future Outlook

Factor	Outlook	Implications
Market Volume	Declining but still significant	> USD 4 billion in 2023; stabilized with new formulations
Innovations	Focus on abuse deterrence, combination drugs	Potential for market repositioning
Regulatory Environment	Tightening continues	Risks of further restrictions
Legal and Reputational Risks	High	Need for strategic legal positioning

---

Key Market Drivers and Barriers

Drivers	Barriers
Chronic pain prevalence	Regulatory restrictions
Need for effective pain control	Societal opioid misuse concerns
Abuse-deterrent formulations	Competition from non-opioid therapies
Physician demand for safer opioids	Legal liabilities

---

Conclusion

Although OXYCONTIN historically dominated the extended-release opioid market, its future dependence on regulatory acceptance, legal environment, and reformulation strategies define its investment potential. The market is shifting toward non-opioid alternatives and abuse-deterrent versions, necessitating continuous innovation. While opportunities exist through product reformulation and geographic expansion, substantial risks from legal liabilities and societal perception remain.

---

Key Takeaways

• Market decline: OXYCONTIN’s market share has sharply declined since 2010 amid regulatory crackdowns and the opioid epidemic.
• Management of legal liabilities: Future investments should consider liabilities stemming from past litigation and ongoing legal risks.
• Innovation focus: Abuse-deterrent formulations and combination drugs present growth avenues but require significant R&D investment.
• Regulatory landscape: An unpredictable environment remains a critical risk factor; investors must monitor policy shifts.
• Strategic diversification: Companies should consider expanding into non-opioid pain management to offset declining opioid sales.

---

FAQs

Q1: Will OXYCONTIN regain market dominance?
Unlikely in the current regulatory and societal climate. Market share may stabilize or further decline unless innovative, safer formulations gain approval and acceptance.

Q2: How do abuse-deterrent formulations impact the market?
They serve as a key differentiation, potentially restoring prescriber confidence and extending product lifecycle but with high development costs and uncertain reimbursement.

Q3: What macroeconomic factors influence OXYCONTIN’s financial trajectory?
Regulatory policies, litigation outcomes, healthcare reimbursement trends, and the societal stance on opioids significantly impact revenue and profitability.

Q4: Are emerging markets viable for OXYCONTIN?
Potential exists due to rising healthcare infrastructure, but regulatory barriers and the global push to limit opioid access pose challenges.

Q5: What alternative therapies threaten OXYCONTIN’s market share?
Non-opioid pharmacotherapies, medical devices, and interventional pain management techniques are increasingly adopted as safer options.

---

References

[1] MarketWatch. "Global Pain Management Drugs Market, 2022."
[2] IQVIATM. "Pain Management Market Trends," 2022.
[3] CDC Prescription Data. "Prescription Opioid Distribution," 2010–2020.
[4] FDA. "Opioid Reformulation and Abuse Deterrence," 2010.